TLR3 Expression is a Potential Prognosis Biomarker and Shapes the Immune-Active Tumor Microenvironment in Esophageal Squamous Cell Carcinoma
Ruibing Su,Lijun Cai,Pan Xiong,Zhiwei Liu,Shaobin Chen,Xi Liu,Runhua Lin,Zhijin Lei,Dongping Tian,Min Su
DOI: https://doi.org/10.2147/JIR.S348786
IF: 4.5
2022-02-28
Journal of Inflammation Research
Abstract:Ruibing Su, 1, &ast Lijun Cai, 1, &ast Pan Xiong, 1, &ast Zhiwei Liu, 1, &ast Shaobin Chen, 2 Xi Liu, 1 Runhua Lin, 1 Zhijin Lei, 1 Dongping Tian, 1 Min Su 1 1 Institute of Clinical Pathology, Department of Pathology, Shantou University Medical College, Shantou, Guangdong, People's Republic of China; 2 Department of Thoracic Surgery, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, People's Republic of China &astThese authors contributed equally to this work Correspondence: Min Su, Institute of Clinical Pathology, Department of Pathology, Shantou University Medical College, No. 22 Xinling Road, Shantou, Guangdong, People's Republic of China, Tel/Fax +86-754-88900429, Email Background: Toll-like receptor 3 (TLR3) not only plays a crucial role in innate immune and inflammation but also in anti-cancer immunity. Nevertheless, the clinicopathological outcome of TLR3 in ESCC is still ambiguous. Methods: Immunohistochemistry was performed to investigate TLR3 expression and its impact on survival in 137 ESCC patients (including paired esophageal tissues with different stages of early lesions from 37 patients). Furthermore, we downloaded ESCC RNA-seq datasets (including phenotype and survival data) from The Cancer Genome Atlas (TCGA). The relationship between TLR3 and prognosis, biological landscape, and immune infiltration was assessed to verify the immunohistochemical results of our tissue samples, explore the possible mechanism of prognostic outcomes, and predict the sensitivity of immunotherapy. Results: TLR3 protein expression displayed an increasing trend in the progression through different grades of cellular atypia, from normal, esophageal simple hyperplasia (ESSH), intraepithelial neoplasia (IEN) to ESCC ( P < 0.0083). TLR3 protein had a positive association with inflammation level ( Rho = 0.341, P < 0.001). TLR3 mRNA expression was significantly higher in comparison to adjacent normal tissues ( P < 0.001). Cox regression analysis indicated high TLR3 protein and mRNA expression conferred good prognosis in our samples and TCGA, especially for advanced ESCC patients (TNM stage III and IV). Overexpression of TLR3 resulted in an immune-active microenvironment via the recruitment of immune-active cells including cytotoxic lymphocytes (CTLs), CD8+ T cells, NK cells, dendritic cells, and M1-type macrophages. TLR3 expression was correlated with the pro-inflammatory cytokines and chemokines relating to anti-tumor immunity. Moreover, GSEA analysis indicated upregulated expression of TLR3 could activate the apoptotic pathway. Conclusion: High TLR3 expression in ESCC patients was associated with a more favorable prognosis, immune-active cell infiltration, and an activated apoptotic pathway. TLR3 has potential applications for immunotherapy and immune response prediction in patients with ESCC. Keywords: esophageal squamous cell carcinoma, TLR3, prognosis, immune infiltrates, immunotherapy response Esophageal squamous cell carcinoma (ESCC), accounting for about 90% of esophageal cancer (ESCA) cases worldwide, is one of the most common and mortal tumors, especially in East Asia. 1,2 ESCC ranked sixth and fourth, respectively, for morbidity and mortality among all malignant tumors in China. 3 However, among the common tumor types, research on ESCC is comparatively insufficient. Despite the advanced development of endoscopic technology in recent years, early diagnosis and therapeutics remain limited for ESCC patients, with a large proportion of tumors being unresectable or have already metastasized when diagnosis and a 5-year survival rate of only approximately 20% in most countries. 4,5 Toll-like receptors (TLRs) are a family of transmembrane receptors that recognize a variety of pathogens, play a vital role in inflammation related to molecular patterns, and have been confirmed to be related to tumor progression or regression, depending on the TLRs and cancer types. 6,7 Toll-like receptor 3 (TLR3), as one of the essential members in TLRs, participates in the carcinogenesis of a variety of tumors. 8,9 TLR3 is expressed in normal epithelial cells, immune cells and cancer cells and recognized as a prognostic biomarker in certain cancers, such as gastric cancer, hepatocellular carcinoma, lung adenocarcinoma, renal cancer, and melanoma. 10,11 Multiple researches have demonstrated that TLR3 agonists can activate specific immune reactivities in the mice tumor models and cancer patients, especially -Abstract Truncated-
immunology